Triple-Negative First-Line Study: Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A, a Pdl-1 Inhibitor in Patients With Triple Negative Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel
- Indications Breast cancer; Male breast cancer
- Focus Therapeutic Use
- 20 Feb 2018 Planned End Date changed from 1 Feb 2021 to 1 Feb 2022.
- 13 Jun 2017 Status changed from active, no longer recruiting to recruiting.
- 10 Jun 2017 Biomarkers information updated